Fig. 1 · Structure
Documents & Downloads
Sutetinib
Tyrosine Kinase Inhibitor
Sutetinib is an orally bioavailable inhibitor primarily targeting tyrosine kinases, including VEGFR and PDGFR, with high affinity (Ki= 0.009 µM for VEGFR-1/2/3 and Ki= 0.008 µM for PDGFR-α/β) and the c-KIT proto-oncogene. It effectively inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts. Sutetinib demonstrates broad-spectrum antitumor activity, making it a valuable tool for cancer research and therapeutic applications.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1259519-20-4 |
| Applications | Tyrosine Kinase Inhibitor |
| Formula | C26H25N5O2 |
| Molecular Weight | 439.51 |
| SMILES | CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(C#C)=CC=C3)=C(C#N)C=N2 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.